Bridging the Coverage Gap
Eli Lilly has launched a new program designed to encourage employers to add coverage for GLP-1 receptor agonist drugs to their employee health plans. The initiative addresses one of the most significant barriers to widespread access to medications like tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management. While demand for these drugs has surged, many employer-sponsored health plans have been reluctant to cover them due to their high cost and the potential budget impact of widespread use.
The program offers employers a structured framework for adding GLP-1 coverage, including negotiated pricing tiers, clinical criteria for patient eligibility, and outcome-based contracts that tie a portion of Lilly's compensation to measurable health improvements in covered employees. This approach shifts some of the financial risk from employers to the drug manufacturer, potentially making coverage more palatable for cost-conscious benefits managers.
Why Employers Have Hesitated
The economics of GLP-1 coverage have given employers pause. At list prices exceeding one thousand dollars per month per patient, covering these medications for even a fraction of eligible employees can add millions to an employer's annual health spending. Large self-insured employers — those that pay claims directly rather than through an insurance carrier — are particularly exposed to this cost, as they bear the full financial impact of utilization increases.
Pharmacy benefit managers have reported that GLP-1 drugs are already among the top contributors to drug spending growth, even with relatively limited coverage. Employers fear that adding explicit coverage could unleash pent-up demand, with a significant percentage of their workforce seeking prescriptions. Weight management drugs are especially challenging because the eligible population is potentially enormous — more than forty percent of American adults meet clinical criteria for obesity treatment.
